Combined with clinical experimental data, it is found that DZXXI can reduce blood lipids, blood viscosity and serum adhesion molecules in the treatment of cerebrovascular diseases, thereby reducing platelet aggregation, increasing blood flow in brain tissue, improving blood supply, and reducing inflammatory factors TNF-α, IL-6 and the apoptotic factor caspase-3, thereby reducing the damage after cerebral ischemia and cerebral infarction (Wang JL. The gene discussed is CASP3; the disease is cerebrovascular disorder.